Author:
Boulenc Xavier,Nicolas Olivier,Hermabessière Stéphanie,Zobouyan Isabelle,Martin Valérie,Donazzolo Yves,Ollier Céline
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference18 articles.
1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–832
2. Boulenc X, Barberan O (2011) Metabolic-based drug–drug interactions prediction, recent approaches for risk assessment along drug development. Drug Metabol Drug Interact 26(4):147–168
3. Brown HS, Ito K, Galetin A, Houston JB (2005) Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Pharmacol 60(5):508–518
4. Djebli N, Rauch C, Fabre D, Boulenc X (2009) Quantification of the pharmacokinetic inhibition of a CYP3A4/CYP2D6 substrate with low hepatic first pass effect and long terminal half-life; importance of study design and inhibition mechanism: a simulation study. Global Metabolism and Pharmacokinetics, Poster at ISSX meeting, Baltimore, USA
5. European Medicines Agency Guideline on the Investigation of Drug Interactions (2012) Committee for human medicinal products (CHMP). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf . Accessed 4 July 2013
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献